FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis

    NEXT STORY
    Curetis Reports Financial Results for the First Six Months of 2019
    PREV STORY
    Translate Bio Announces Pricing of Public Offering of Common Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Translate Bio to Present at Jefferies Virtual Healthcare Conference

    author_avatar
    NASDAQ Market News

    Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

    author_avatar
    NASDAQ Market News

    Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry

    author_avatar
    NASDAQ Market News